Brain Fog

'Brain fog' is not a clinical diagnosis. It is a colloquial term covering the experience of slowed thinking, difficulty concentrating, mild word-finding trouble, and a sense of mental sluggishness that can accompany sleep deprivation, stress, post-viral states (notably post-COVID and post-mononucleosis), perimenopause, ADHD, depression, hypothyroidism, anemia, chronic inflammation, and aging. Because the underlying cause varies, the peptide conversation around brain fog spans a wide territory — from mild cognitive enhancement compounds with limited Russian and Soviet-era clinical history to investigational neurotrophic peptides being studied for serious cognitive disease.

The peptides discussed for brain fog cluster into two groups. The first is the Russian-Soviet nootropic family — Semax (a heptapeptide derived from ACTH(4-10)) and Selank (a synthetic analog of tuftsin) — both developed at Russian institutes in the 1980s-90s and approved in Russia and a few neighboring countries for cognitive and anxiety indications. The second is the neurotrophic family — Cerebrolysin (a porcine brain-derived peptide mixture used clinically in Europe and Asia for stroke and neurodegenerative disease), Dihexa (an experimental angiotensin IV analog with hepatocyte growth factor agonist activity), GSB-106 (a low-molecular-weight BDNF mimetic), and PE-22-28 (an investigational peptide for cognitive endpoints).

This page covers what these peptides do, what the evidence actually shows for cognitive enhancement, and how to think about peptides relative to addressing the upstream drivers that usually underlie brain fog. The latter point matters: brain fog driven by sleep debt is fixed by sleep, not by peptides. Brain fog driven by hypothyroidism is fixed by thyroid replacement. Peptides for brain fog work best — when they work — as adjuncts to addressing the cause, not substitutes for diagnosis.

How peptides target brain fog

Six peptides come up repeatedly in cognitive and brain fog discussions. First, Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) without the steroidogenic activity of the parent hormone. It increases BDNF expression in the hippocampus and prefrontal cortex in animal models, has documented effects on dopaminergic and serotonergic systems, and has been used in Russian clinical practice since the 1990s for stroke recovery, attention deficit, and cognitive enhancement. It is administered intranasally for direct nose-to-brain delivery.

Second, Selank is a synthetic 7-amino-acid analog of tuftsin developed at the Institute of Molecular Genetics in Moscow. It has anxiolytic effects without the sedation or dependence profile of benzodiazepines, modulates GABA, serotonin, and BDNF systems, and is approved in Russia for generalized anxiety disorder. The cognitive benefits reported are largely attributed to anxiety reduction unmasking baseline cognitive capacity rather than direct cognitive enhancement.

Third, Cerebrolysin is a porcine-brain-derived peptide preparation containing low-molecular-weight peptides and free amino acids, used clinically in over 50 countries (primarily Europe, Russia, and Asia) for stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease. It has neurotrophic effects mimicking brain-derived neurotrophic factors and is supported by multiple randomized controlled trials in stroke and dementia indications.

Fourth, Dihexa is an experimental 6-amino-acid peptide (N-hexanoic-Tyr-Ile-(6) amino hexanoic amide) derived from angiotensin IV that acts as a hepatocyte growth factor / c-Met receptor activator. In animal models it produces dramatic dendritic spine formation and reverses cognitive deficits in aged rats. Human data are very limited.

Fifth, GSB-106 is a low-molecular-weight BDNF mimetic developed at the Russian Academy of Sciences with antidepressant and cognitive activity in animal models.

Sixth, PE-22-28 is a peptide derived from spadin with reported antidepressant and cognitive endpoints in preclinical research.

What the evidence shows

Cerebrolysin has the strongest controlled-trial evidence in this group. Multiple Phase III randomized trials in acute ischemic stroke (CASTA trial in 2012, others) and vascular dementia have shown modest but consistent improvements in cognitive and functional endpoints. The clinical use base in Europe, Russia, and Asia is decades long. The compound is not FDA-approved for any indication in the United States.

Semax has Russian clinical use since the 1990s with multiple smaller trials in stroke recovery, attention deficit, and post-stroke cognitive impairment. The methodology of much of this literature is below modern Western standards (smaller samples, less rigorous blinding, often unblinded efficacy comparisons). The mechanism work is more rigorous and supports a real BDNF-mediated effect. Selank has a similar evidence pattern — Russian clinical history for anxiety, mechanistic basic science, limited Western controlled validation.

Dihexa, GSB-106, and PE-22-28 are at the preclinical-evidence stage with limited or no human controlled trial data. Animal effects are striking but rodent cognitive enhancement does not translate cleanly to humans — many compounds with dramatic rodent effects have failed to produce human cognitive improvement at effect sizes comparable to caffeine or methylphenidate.

For brain fog specifically — as opposed to validated diagnostic categories like vascular dementia or post-stroke cognitive impairment — none of these peptides has controlled trial evidence in the brain fog use case. People who report benefit from Semax, Selank, or Cerebrolysin for brain fog are often experiencing real subjective improvement, but the evidence base does not yet rise to controlled-trial validation.

What to expect

Reported regimens vary widely. Semax 1% intranasal solution at 200-1000 mcg per dose, 1-3 times daily for 1-4 weeks is the most common protocol. Onset of subjective effect is often within 30-60 minutes after dose, with cumulative effects building over the course. Selank 0.15% intranasal at similar dosing intervals is used for anxiety-prominent presentations. Cerebrolysin in clinical use is administered intramuscularly or intravenously over courses of 10-20 days, typically with 1-3 mL daily; subcutaneous self-administration is sometimes done off-label. Dihexa, GSB-106, and PE-22-28 dosing is less established and largely investigational.

Magnitude of expected effect: subtle. People who report response generally describe a modest improvement in concentration, mental clarity, or motivation — closer in magnitude to good caffeine on a well-rested day than to stimulant medication. The often-claimed 'limitless pill' narrative is not what these compounds deliver in practice.

For brain fog specifically, identifying and addressing the driver almost always produces larger effects than peptides alone. Sleep optimization (consistent 7-9 hours, sleep apnea evaluation if indicated), thyroid panel, ferritin and B12 levels, metabolic workup, and stress and depression screening will catch the bulk of brain fog causes. Peptides become reasonable adjuncts after these have been addressed.

Frequently asked questions

Part of these goals

Related conditions

• Anxiety
• Chronic Fatigue

Stacks that overlap

• Semax + Selank (The Nootropic Stack)

  The Russian nootropic peptide combination — Semax for cognitive enhancement and BDNF upregulation paired with Selank for anxiolytic effects and stress resilience.